Vol.26/No.12

Mutahar Ahmed, MD, FACS, details the transvesical surgical approach for radical prostatectomy.

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Justin Taylor, MD, discusses findings from a study that evaluated the ability of ChatGPT to offer specific information in hematologic malignancies.

Daniel P. Petrylak, MD, discusses key data in MIBC presented during the 2025 ESMO Congress and previews the 19th Annual New York GU Cancers Congress.

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

In a recent Peer Exchange, breast cancer experts discussed updates from ESMO 2025, including practice-informing data with antibody-drug conjugates.

Primo Nery Lara, Jr, MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.